Treatment for aerobic vaginitis using Baofukang vaginal suppository
Medical Ethics Committee of Peking University Shenzhen Hospital
This study tests if a new vaginal suppository can help women with aerobic vaginitis feel better, comparing two different treatment lengths of 7 days and 14 days.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years to 55 Years |
| Sex | Female |
| Sponsor | Peking University Shenzhen Hospital Academic / other |
| Locations | 1 site (Shenzhen, Guangdong) |
| Trial ID | NCT04574089 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the efficacy and safety of Baofukang vaginal suppository in treating aerobic vaginitis. Participants are divided into two groups, receiving either a 7-day or a 14-day course of treatment. The effectiveness of the treatment will be assessed 7 to 14 days and 35 to 42 days after the completion of the regimen. The study aims to provide insights into the optimal duration of treatment for this condition.
Who should consider this trial
Good fit: Ideal candidates for this study are women diagnosed with aerobic vaginitis who meet specific inclusion criteria.
Not a fit: Patients with other types of vaginitis, serious underlying health conditions, or those who are pregnant or lactating may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide an effective solution for women suffering from aerobic vaginitis.
How similar studies have performed: While this approach is being evaluated in this trial, similar studies have shown promise in treating vaginitis with localized therapies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Aerobic vaginitis diagnosed based on present ： 1. Vaginal dischareg ; 2. pH \> 4.5; 3. Donders score≥3; Exclusion Criteria: 1. Patients with other vaginitis, cervical erosion, or suspected gonorrhea, herpes simplex virus infection and other vulvar diseases; 2. Patients received systemic or vaginal antifungal or antibiotic treatment within two weeks before admission. 3. Pregnancy, lactation and intentional pregnancy; 4. Women with liver and kidney dysfunction, low immune function, diabetes, psychosis or other serious diseases; 5. Allergic constitution and patients allergic to drug ingredients in this study; 6. Those with poor compliance.
Where this trial is running
Shenzhen, Guangdong
- Peking University Shenzhen Hosptal — Shenzhen, Guangdong, China (Recruiting)
Study contacts
- Principal investigator: Shangrong Fan, M.D. — Dept of Obstetrics and Gynecology,Peking University Shenzhen Hospital
- Study coordinator: Ping Liu, M.D.
- Email: 253783006@qq.com
- Phone: 86755-83923333
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.